Lilly, Merck, Pfizer starting research center

Back to TopCommentsE-mailPrintBookmark and Share

Three major U.S. drugmakers, Eli Lilly and Co., Merck & Co. and Pfizer Inc., said Tuesday they have formed a not-for-profit company in Asia to focus on cancer research and treatments.

Eli Lilly is based in Indianapolis, Merck is based in Whitehouse Station, N.J., and Pfizer is based in New York.

The companies said they formed the Asian Cancer Research Group to focus on the most commonly diagnosed cancers in Asia, including lung and gastric cancers.

They did not say in a news release how much funding they were committing to the project.

Over the next two years, Lilly, Merck and Pfizer said they will create an extensive database that will be made available to researchers.

"The goal of the Asian Cancer Research Group is to improve the knowledge of cancers prevalent in Asia and to accelerate drug discovery efforts by freely sharing the resulting data with the scientific community," the companies said.

They said as many as 40 percent of patients with lung cancer in Asia demonstrate a mutation that is relatively rare in Western patients, suggesting a different research approach is needed for developing treatments. Meanwhile, the companies said gastric cancer is the second largest cause of cancer death in the world, killing more than 630,000 patients per year, more people than all cancers combined in the United States.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
thisissue1-092914.jpg 092914

Subscribe to IBJ